Vitamin K
Vitamin K’s skin relevance is wider than its coagulation association suggests, and the K1/K2 distinction matters. Both forms act as cofactors for γ-glutamyl carboxylase (GGCX), enabling the carboxylation of glutamate residues in vitamin K-dependent proteins (VKDPs) – converting inactive Glu proteins to active Gla proteins. In skin-relevant terms, K1 drives carboxylation of coagulation factors that determine haematoma clearance speed, and topical K1 has RCT evidence for accelerating wound healing and supporting bruise resolution. K2 – specifically the longer-chain MK-4 and MK-7 forms – activates matrix Gla protein (MGP) in vascular and soft tissue, preventing the calcium deposition in elastin fibres that drives dermal stiffening with age. The K2/MGP/elastin calcification pathway connects vitamin K directly to structural dermal ageing in a mechanism that parallels, and interacts with, glycation-driven collagen rigidity.
Vitamin K is a family of fat-soluble compounds united by a 2-methyl-1,4-naphthoquinone core and distinguished by their side chains. Vitamin K1 (phylloquinone) has a phytyl side chain and is the primary plant-source form, found in green leafy vegetables. Vitamin K2 encompasses a series of menaquinones (MK-4 through MK-13) differentiated by the number of isoprenoid units in their side chains, MK-4 and MK-7 being the most clinically studied. Vitamin K3 (menadione) is a synthetic form not used in human supplementation due to toxicity. [1]
All biologically active vitamin K forms function as cofactors for γ-glutamyl carboxylase (GGCX), the enzyme that carboxylates specific glutamate (Glu) residues in vitamin K-dependent proteins (VKDPs) to γ-carboxyglutamate (Gla). This carboxylation is the activation step – without it, VKDPs are synthesised but non-functional. The vitamin K cycle that enables repeated GGCX activity involves the reduction of vitamin K epoxide back to the active hydroquinone form by vitamin K epoxide reductase (VKORC1) – the enzyme that warfarin inhibits, explaining why anticoagulant therapy impairs all vitamin K-dependent functions simultaneously. [2]
K1 and the Coagulation/Haemostasis Route
Vitamin K1 is preferentially taken up by the liver, where it drives carboxylation of the clotting factors (II, VII, IX, X) and anticoagulant proteins (C, S, Z) that constitute the coagulation cascade. In skin terms, this is the mechanism by which vitamin K status influences bruise formation, haematoma clearance, and wound haemostasis – how quickly bleeding stops after tissue disruption, and how efficiently the resulting haematoma is broken down and cleared.
Topical vitamin K1 has a clinically meaningful evidence base for wound healing and bruise resolution that is independent of systemic coagulation status. A randomised controlled trial of topical vitamin K1 cream on full-thickness wounds found significant improvements over control in wound contraction rate, epithelialisation time, hydroxyproline content, and wound tensile strength – histopathological examination confirmed improved collagen fibre organisation and vascularity in the vitamin K group. [4] A second RCT using topical K1 on high-frequency electrocautery wounds found significantly faster healing at 14 days compared to control. [3]
The precise topical mechanism is not as fully characterised as the systemic coagulation pathway. Proposed mechanisms include local activation of coagulation factors in the perivascular tissue, promotion of fibroblast proliferation, and a direct effect on collagen synthesis – vitamin K deficiency in rats reduced skin collagen content with a corresponding increase in free hydroxyproline, suggesting a role in collagen stabilisation as well as synthesis. [4]
The bruising-specific evidence is more mixed. A 1% topical vitamin K cream study using autologous blood injected intradermally showed bruise clearance in 5–8 days versus 11–13 days without treatment, which is a meaningful difference. However, a controlled study of topical vitamin K before laser treatment found no significant difference in post-laser bruising compared to placebo. sciencedirect.com The distinction may relate to mechanism: injected haematoma involves extravascular blood requiring reabsorption through local coagulation factor-dependent pathways that topical K1 can influence; laser-induced vascular damage involves different tissue repair dynamics. The evidence supports topical K1 for haematoma resolution after procedures, with less certainty for pre-procedure bruise prevention.
K2, MGP, and Elastin Calcification
Vitamin K2 – particularly the longer-chain MK-4 and MK-7 forms – is preferentially distributed to extrahepatic tissues including bone, vessel walls, and skin. [6] Here it activates matrix Gla protein (MGP), the most potent known inhibitor of soft tissue calcification. MGP is expressed in the extracellular matrix of vascular smooth muscle and, critically for skin, in dermal fibroblasts; it is produced in and around elastin-rich tissue.
The mechanism is precise: uncarboxylated MGP (ucMGP) cannot bind calcium ions effectively; carboxylated MGP (cMGP), activated by vitamin K2-dependent GGCX, binds free calcium and prevents its deposition in elastin fibres and surrounding ECM. Elastin calcification – the progressive deposition of calcium into elastic fibres – is a well-characterised component of dermal ageing that reduces elastin’s stretch-and-recoil capacity, contributing to skin laxity and the loss of spring-back that characterises aged skin. Where glycation produces collagen rigidity through cross-linking, elastin calcification produces elastin rigidity through mineralisation – two parallel mechanisms operating on different structural proteins, both progressive, both contributing to the mechanical stiffness and surface appearance of chronologically aged skin.
Adequate vitamin K2 status does not reverse existing elastin calcification; cMGP prevents further deposition but cannot dissolve established calcium deposits. The intervention is therefore most effective as a long-term prevention strategy rather than a treatment for established calcification. Circulating ucMGP is used in cardiovascular research as a biomarker of vitamin K2 insufficiency; high ucMGP indicates inadequate MGP carboxylation in soft tissues broadly, including dermis.
K2, Collagen, and the MK-4 Connection
Beyond elastin calcification, MK-4 specifically has been shown to increase collagen accumulation in osteoblast models, with MK-7 also confirmed to increase collagen production. [5] The mechanism likely involves GGCX-dependent carboxylation of other VKDPs involved in ECM organisation – osteocalcin in bone, and potentially dermal equivalents. This collagen-supporting activity is less directly studied in skin than in bone, but the shared GGCX pathway and the presence of VKDPs in dermal fibroblasts makes it mechanistically plausible rather than speculative.
K1 vs K2: Why Both Matter
The K1/K2 distinction has practical implications that are rarely articulated in skincare content:
| Property | Vitamin K1 (Phylloquinone) | Vitamin K2 MK-4/MK-7 |
|---|---|---|
| Primary tissue destination | Liver | Extrahepatic (bone, vessels, skin) |
| Primary VKDP targets | Coagulation factors II, VII, IX, X | MGP, osteocalcin, Gas6 |
| Skin mechanism | Haemostasis, wound healing, bruise resolution | Elastin calcification prevention, collagen support |
| Relevant application | Topical (wound/bruise) + dietary | Systemic supplementation |
| Half-life | Short (~1–2 hours) | MK-7: long (~72 hours); MK-4: short |
| Dietary sources | Green leafy vegetables | Fermented foods (natto), grass-fed dairy, egg yolk, tallow |
The long half-life of MK-7 is clinically significant for supplementation: its extended plasma residence means once-daily dosing achieves more consistent tissue saturation than MK-4, which requires multiple daily doses for equivalent soft tissue carboxylation. [6]
Vitamin K in Tallow and Animal-Source Foods
Grass-fed tallow contains both vitamin K1 (from the animal’s dietary plant intake, stored in fat tissue) and vitamin K2 as MK-4 (converted from K1 in animal tissues through UBIAD1 enzyme activity – this K1→MK-4 conversion is a distinct biological synthesis pathway in animal tissue). Both are fat-soluble and heat-stable, surviving the rendering process at meaningful concentrations, consistent with vitamin E in this regard and distinctly different from the water-soluble vitamin B12. [2] The MK-4 content of grass-fed animal fat reflects the K1→MK-4 conversion that occurs in adipose tissue, making it genuinely distinct from plant-source K1. Whether topically applied tallow-derived vitamin K exerts the localised wound-healing effects seen in purpose-formulated 1% K1 cream studies is unconfirmed; the concentrations in tallow are lower and variable compared to standardised formulations.
Clinical Application
Vitamin K creates two distinct clinical questions. For topical application – post-procedure bruising, haematoma resolution, wound healing acceleration – K1 is the relevant form, and the evidence supports its use in the recovery phase. For systemic skin-ageing prevention – protecting elastin from calcification and supporting the ECM environment – K2’s MGP carboxylation mechanism is the relevant pathway, and it operates over years rather than weeks.
Topical K1: Post-Procedure Recovery
The RCT evidence for topical K1 in wound healing supports its inclusion in post-procedure recovery formulations, particularly where haematoma formation, bruising, or slow re-epithelialisation is a concern. Procedures most relevant:
Injectable treatments: dermal fillers, iPRF, polynucleotide injections – all involve needle trauma with haematoma risk. Post-procedure topical K1 application supports haematoma clearance through the local coagulation factor carboxylation pathway. The evidence specifically supports application after bruising has formed, accelerating resolution rather than preventing vascular injury.
Laser and energy-based treatments: the pre-procedure application evidence for bruise prevention is less convincing than post-procedure application for clearance, as established in the full description. The clinical recommendation is post-treatment application once the acute wound response is established rather than pre-treatment prophylaxis.
Periorbital dark circles: undereye dark circles often have a haematic component (pooled haemosiderin from chronic microhaemorrhage) alongside melanin and structural shadow components. The K1 coagulation mechanism addresses the haematic component specifically, which is why vitamin K eye creams have a rational (if modest-evidence) basis for this presentation, distinct from brightening or volume-restoration approaches. Identifying which component predominates in a given client helps frame whether topical K1 is likely to contribute meaningfully.
Topical K1 is compatible with the standard post-procedure protocol established across other entities – ceramides, dexpanthenol, hyaluronic acid, niacinamide. There are no known interactions between topical K1 and these barrier repair or anti-inflammatory ingredients.
Systemic K2: Long-Term Structural Support
For clients concerned with skin laxity, elastin loss, or structural ageing – particularly in the 45+ age group where elastin calcification accumulation becomes clinically visible – K2 supplementation as MK-7 is the appropriate recommendation. At doses of 100–200 µg MK-7 daily, the evidence supports meaningful reduction in circulating ucMGP (indicating improved MGP carboxylation) with consistent use. [6]
The K2 recommendation connects directly to the parallel ageing mechanisms established in the Glycation entity: glycation produces collagen rigidity through AGE cross-linking; elastin calcification produces elastin rigidity through mineralisation. A client managing skin structural ageing comprehensively is addressing both – dietary approaches that reduce glycation (glycaemic management) alongside K2 supplementation that maintains MGP-mediated elastin protection.
The D3 + K2 combination merits specific mention. As established in the Vitamin D entity, vitamin D3 increases calcium absorption and utilisation. Without adequate K2/MGP activity, this increased calcium availability raises the risk of soft tissue and vascular calcification – calcium directed toward bone formation rather than soft tissue deposition requires active MGP to prevent the latter. The D3 + K2 pairing is therefore not merely additive; it is mechanistically complementary. Recommending vitamin D3 supplementation – particularly at the 2000–4000 IU doses supported in the Vitamin D entity – without K2 co-supplementation in clients at risk of soft tissue calcification is incomplete nutritional guidance.
For clients using GLP-1 medications with significant fat mass reduction underway, the redistribution of fat-soluble vitamins (including both K1 and K2) from adipose stores back into circulation should be considered. As adipose vitamin K stores decrease with fat mass, monitoring K status becomes relevant; this mirrors the vitamin D adipose sequestration dynamic established in the Vitamin D entity.
References
Chatron N, Hammed A, Benoît E, et al. (2019). Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1. Nutrients, 11(1) . doi.org/10.3390/nu11010067
Halder M, Petsophonsakul P, Akbulut AC, et al. (2019). Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease. Int J Mol Sci, 20(4) . doi.org/10.3390/ijms20040896
Hemmati AA, Houshmand G, Ghorbanzadeh B, et al. (2014). Topical vitamin K1 promotes repair of full thickness wound in rat. Indian J Pharmacol, 46(4), 409-12 . doi.org/10.4103/0253-7613.135953
Pazyar N, Houshmand G, Yaghoobi R, et al. (2019). Wound healing effects of topical Vitamin K: A randomized controlled trial. Indian J Pharmacol, 51(2), 88-92 . doi.org/10.4103/ijp.ijp_183_18
Sato T, Inaba N, Yamashita T (2020). MK-7 and Its Effects on Bone Quality and Strength. Nutrients, 12(4) . doi.org/10.3390/nu12040965
Schwalfenberg GK (2017). Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health. J Nutr Metab, 2017, 6254836 . doi.org/10.1155/2017/6254836